Drug Trial Radar · NCT07294508
A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer
Last checked: Nov 19, 2026Latest source record: Mar 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
706
Planned (sponsor's estimate)
Start
Feb 27, 2026
Primary completion
Jan 15, 2028
Study completion Dec 30, 2030
Sponsor
- Lead sponsor
- Shanghai Henlius BiotechIndustry
- Sponsor type
- Industry
- First posted
- Dec 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the clinical efficacy of HLX22 in combination with HLX87 as first-line treatment in patients with HER2-positive recurrent or metastatic breast cancer
Conditions
- HER2 + Breast Cancer
Interventions
HLX87 + HLX22Drug
HLX87 is a novel HER2-targeted ADC with a similar mechanism of action to trastuzumab deruxtecan. HLX22 is a novel monoclonal antibody targeting HER2 .
HLX87 + PertuzumabDrug
HLX87 is a novel HER2-targeted ADC with a similar mechanism of action to trastuzumab deruxtecan
T-Dxd + PertuzumabDrug
T-Dxd is a HER2-targeted ADC
THPDrug
Pertuzumab+ Trastuzumab+Docetaxel
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR) (assessed by the blinded independent central review [BICR] as per RECIST v1.1)Time frame: up to 26 months
- Progression-free survival (PFS) (assessed by BICR as per RECIST v1.1)Time frame: up to 37 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.